| Trial ID: | L2200 |
| Source ID: | NCT05041673
|
| Associated Drug: |
Metformin
|
| Title: |
Anti-diabetic Drugs and Fatty Liver Management
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Fatty Liver, Nonalcoholic|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Metformin
|
| Outcome Measures: |
Primary: Change in steatosis as measured using CAP score (fibroscan) and MRI, 12 months | Secondary: Change in liver enzymes, 12 months|Changes in fibrosis grade, as measured by transient elastography (Fibroscan), 12 months
|
| Sponsor/Collaborators: |
Sponsor: Alexandria University | Collaborators: Eva Pharma
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
120
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2021-02-23
|
| Completion Date: |
2022-09-30
|
| Results First Posted: |
|
| Last Update Posted: |
2022-01-18
|
| Locations: |
Alexandria University., Alexandria, 21131, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT05041673
|
